ArticleTherapeutics and clinical risk management2008

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Martin Henkes et al.PubMed ↗Full text ↗

No numbers read from the abstract.